Table 1

Demographic and baseline characteristics of patients

CS
n=199
Celecoxib
n=199
Placebo
n=205
Age (years)
 Mean (SD) 65.5 (8.0) 65.5 (7.8) 64.9 (8.0)
Sex, n (%)
 Female156 (78.4)160 (80.4)152 (74.1)
Height (cm)
 Mean (SD)163.3 (8.8)162.8 (9.4)164.6 (9.5)
Weight (kg)
 Mean (SD) 80.4 (14.1) 78.4 (13.9) 82.9 (14.7)
BMI (kg/m2)
 Mean (SD) 30.2 (4.7) 29.5 (4.4) 30.6 (5.0)
Time from diagnosis of knee OA (months)
 Mean (SD) 72.3 (69.2) 64.4 (63.4) 69.2 (72.5)
KL grade, n (%)
 Grade 1 48 (24.1) 46 (23.1) 53 (25.9)
 Grade 2100 (50.3)101 (50.8)101 (49.3)
 Grade 3 50 (25.1) 52 (26.1) 51 (24.9)
 Grade 4  1 (0.5)  0 (0.0)  0 (0.0)
Duration of regular pain (months)
 Mean (SD) 41.7 (60.3) 39.9 (56.5) 47.8 (68.1)
Target knee (the most symptomatic)
 Left, n (%) 85 (42.7) 95 (47.7) 92 (44.9)
Target knee pain (VAS, mm)
 Mean (SD) 70.9 (9.8) 69.7 (10.2) 70.0 (10.3)
Lequesne’s Algo-Functional Index (LI total score)
 Mean (SD) 11.8 (2.9) 11.6 (2.9) 11.8 (3.1)
  • BMI, body mass index; KL, Kellgren-Lawrence; LI, Lequesne Index; OA, osteoarthritis; VAS, Visual Analogue Scale.